Spots Global Cancer Trial Database for fgfr
Every month we try and update this database with for fgfr cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling | NCT01868022 | Neoplasms | GSK3052230 paclitaxel carboplatin docetaxel pemetrexed cisplatin | 18 Years - | GlaxoSmithKline | |
| Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W) | NCT04439240 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Plas... | FGFR Inhibitor ... | 18 Years - | National Cancer Institute (NCI) | |
| Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer | NCT04965818 | Advanced or Met... Non-Small Cell ... KRAS Gene Mutat... | Futibatinib and... | 18 Years - | Taiho Oncology, Inc. | |
| Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma | NCT04601857 | Advanced and Me... | futibatinib and... | 18 Years - | Taiho Oncology, Inc. | |
| Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF | NCT01367275 | Colorectal Canc... Colorectal Aden... | Brivanib Irinotecan | 18 Years - | M.D. Anderson Cancer Center | |
| A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma | NCT03656536 | Unresectable Ch... Metastatic Chol... | Pemigatinib Gemcitabine Cisplatin | 18 Years - | Incyte Corporation | |
| Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies | NCT04149691 | Gastric Cancer Bladder Cancer Squamous Non-sm... Cholangiocarcin... Sarcoma Endometrial Can... Other Solid Tum... | CPL304110 | 25 Years - | Celon Pharma SA | |
| A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma | NCT03656536 | Unresectable Ch... Metastatic Chol... | Pemigatinib Gemcitabine Cisplatin | 18 Years - | Incyte Corporation | |
| Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W) | NCT04439240 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Plas... | FGFR Inhibitor ... | 18 Years - | National Cancer Institute (NCI) | |
| Pemigatinib for FGF/FGFR Alterations Advanced Pan Solid Tumors | NCT06022289 | Solid Tumor FGF Receptor Ge... FGF Amplificati... FGF Receptor Ge... FGF Receptor Ge... | Pemigatinib | 18 Years - | Tianjin Medical University Second Hospital | |
| Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling | NCT01868022 | Neoplasms | GSK3052230 paclitaxel carboplatin docetaxel pemetrexed cisplatin | 18 Years - | GlaxoSmithKline | |
| A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies | NCT01004224 | Advanced Solid ... Squamous Lung C... Bladder Cancer ... Advanced Solid ... Advanced Solid ... Advanced Solid ... | BGJ398 | 18 Years - | Novartis | |
| Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib | NCT01831726 | Tumor Pathway A... | Dovitinib (TKI2... | 18 Years - 100 Years | Novartis | |
| Pemigatinib for FGF/FGFR Alterations Advanced Pan Solid Tumors | NCT06022289 | Solid Tumor FGF Receptor Ge... FGF Amplificati... FGF Receptor Ge... FGF Receptor Ge... | Pemigatinib | 18 Years - | Tianjin Medical University Second Hospital | |
| Pemigatinib for FGF/FGFR Alterations Advanced Pan Solid Tumors | NCT06022289 | Solid Tumor FGF Receptor Ge... FGF Amplificati... FGF Receptor Ge... FGF Receptor Ge... | Pemigatinib | 18 Years - | Tianjin Medical University Second Hospital | |
| A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma Patients | NCT01576380 | Adenocarcinoma,... Linitis Plastic... Stomach Neoplas... Stomach Disease... Neoplasms by Si... Neoplasms | TKI258 | 20 Years - | Novartis | |
| A Study of TAS-120 in Patients With Metastatic Breast Cancer | NCT04024436 | Metastatic Brea... FGFR 1 High Amp... FGFR2 Amplifica... | Futibatinib Futibatinib plu... | 18 Years - | Taiho Oncology, Inc. | |
| A Study of TAS-120 in Patients With Metastatic Breast Cancer | NCT04024436 | Metastatic Brea... FGFR 1 High Amp... FGFR2 Amplifica... | Futibatinib Futibatinib plu... | 18 Years - | Taiho Oncology, Inc. | |
| Phase 1b Trial of BGJ398/BYL719 in Solid Tumors | NCT01928459 | Advanced Solid ... Metastatic Soli... | BGJ398 BYL719 | 18 Years - | Novartis | |
| Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer | NCT04965818 | Advanced or Met... Non-Small Cell ... KRAS Gene Mutat... | Futibatinib and... | 18 Years - | Taiho Oncology, Inc. | |
| Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling | NCT01868022 | Neoplasms | GSK3052230 paclitaxel carboplatin docetaxel pemetrexed cisplatin | 18 Years - | GlaxoSmithKline | |
| Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling | NCT02846766 | Cancer | Lenvatinib | 18 Years - | University of California, San Diego | |
| BGJ398 for Patients With Tumors With FGFR Genetic Alterations | NCT02160041 | Solid Tumor Hematologic Mal... | BGJ398 | 18 Years - | Novartis | |
| A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial Carcinoma | NCT02608125 | Solid Tumors Metastatic Urot... | PRN1371 | 18 Years - | Principia Biopharma, a Sanofi Company | |
| A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma Patients | NCT01576380 | Adenocarcinoma,... Linitis Plastic... Stomach Neoplas... Stomach Disease... Neoplasms by Si... Neoplasms | TKI258 | 20 Years - | Novartis | |
| Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF | NCT01367275 | Colorectal Canc... Colorectal Aden... | Brivanib Irinotecan | 18 Years - | M.D. Anderson Cancer Center | |
| Efficacy and Safety of AZD4547 Versus Paclitaxel in Patients With Advanced Gastric or Gastro-oesophageal Cancer | NCT01457846 | Gastro-oesophag... Gastric Cancer | AZD4547 paclitaxel | 25 Years - 130 Years | AstraZeneca | |
| Futibatinib in Patients With Specific FGFR Aberrations | NCT04189445 | Advanced or Met... Advanced or Met... Myeloid or Lymp... | Futibatinib | 18 Years - | Taiho Oncology, Inc. | |
| Anlotinib in Advanced Solid Tumors With FGFR Alteration | NCT03929965 | Advanced Solid ... | Anlotinib | 18 Years - 75 Years | Shanghai Changzheng Hospital | |
| Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations | NCT02747797 | Advanced Cancer | Lucitanib | 18 Years - | University of California, San Diego | |
| Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma | NCT04601857 | Advanced and Me... | futibatinib and... | 18 Years - | Taiho Oncology, Inc. | |
| Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations | NCT01752920 | Solid Tumor | Derazantinib lo... Derazantinib mi... Derazantinib hi... Derazantinib at... | 18 Years - | Basilea Pharmaceutica |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
